Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Intangibles: 2023-2024

Historic Intangibles for ARS Pharmaceuticals (SPRY) over the last 2 years, with Dec 2024 value amounting to $7.4 million.

  • ARS Pharmaceuticals' Intangibles rose 96.39% to $14.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.7 million, marking a year-over-year increase of 96.39%. This contributed to the annual value of $7.4 million for FY2024, which is 1094.65% up from last year.
  • According to the latest figures from FY2024, ARS Pharmaceuticals' Intangibles is $7.4 million, which was up 1,094.65% from $617,000 recorded in FY2023.
  • ARS Pharmaceuticals' 5-year Intangibles high stood at $7.4 million for FY2024, and its period low was $617,000 during FY2023.
  • In the last 2 years, ARS Pharmaceuticals' Intangibles had a median value of $4.0 million in 2023 and averaged $4.0 million.
  • Data for ARS Pharmaceuticals' Intangibles shows a peak YoY spiked of 1,094.65% (in 2024) over the last 5 years.
  • ARS Pharmaceuticals' Intangibles (Yearly) stood at $617,000 in 2023, then surged by 1,094.65% to $7.4 million in 2024.